Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology

Nurix Therapeutics NRIX	0.00	0.00%
ROCHE HOLDINGS AG RHHBF	0.00	0.00%
ROCHE HOLDINGS AG RHHBY	0.00	0.00%
ROCHE HOLDINGS AG RHHVF	0.00	0.00%

Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies
Collaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis)
Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.